Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sonam Cogdill

Physician Assistant Manning, SC Physician Assistant

NPI 1205440955 CMS profile 10521109

12 W South St, Manning, SC 29102

Open in the dashboard

General payments

$893

51 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sonam Cogdill of Manning, SC is reported in the CMS Open Payments database as having received $893 across 51 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $177 10
2024 General $392 21
2023 General $185 10
2022 General $86 6
2021 General $53 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sonam Cogdill
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Sonam Cogdill were reported at $177. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Sonam Cogdill Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $53 $132 $37–$438 $132
2022 $86 $155 $48–$522 $149
2023 $185 $167 $52–$557 $160
2024 $392 $178 $55–$600 $164
2025 $177 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $208 9 payments
  2. AstraZeneca Pharmaceuticals LP $204 12 payments
  3. Novo Nordisk Inc $105 7 payments
  4. AbbVie, Inc. $103 6 payments
  5. GlaxoSmithKline, LLC. $56 3 payments
  6. Merck Sharp & Dohme Corporation $51 4 payments
  7. Phathom Pharmaceuticals, Inc. $33 2 payments
  8. Amgen Inc. $29 2 payments
  9. Dexcom, Inc. $25 1 payment
  10. Hologic, LLC $20 1 payment
  11. Other $60 4 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $893 51 payments
Products named General payments · program years 2021–2025
  1. AIRSUPRA $169 10 payments
  2. RYBELSUS $89 6 payments
  3. Ozempic $75 5 payments
  4. JARDIANCE $73 3 payments
  5. VRAYLAR $65 4 payments
  6. SYNJARDY $62 3 payments
  7. TRELEGY ELLIPTA $56 3 payments
  8. SHINGRIX $56 3 payments
  9. AREXVY $56 3 payments
  10. TRADJENTA $45 2 payments
  11. Other $420 27 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 83 drugs

Part D claims

3,255

Median for Physician Assistant: 241

Drug cost

$284,405

Median for Physician Assistant: $4,110

Branded share of claims

20.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 40 $43,624
Rybelsus Semaglutide Brand 34 $37,367
Jardiance Empagliflozin Brand 34 $33,104
Januvia Sitagliptin Phosphate Brand 37 $30,776
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 32 $22,602
Vraylar Cariprazine Hcl Brand 12 $18,308
Linzess Linaclotide Brand 15 $16,122
Farxiga Dapagliflozin Propanediol Brand 24 $13,843
Breo Ellipta Fluticasone/Vilanterol Brand 27 $11,729
Entresto Sacubitril/Valsartan Brand 12 $10,704

The 10 drugs with the highest cost, of 83 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$25,856

Of which drugs: $93

Medicare patients

172

Average age 73

Services billed

1,089

99 women, 73 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 30%
Ischemic heart disease 22%
Atrial fibrillation 19%
Cancer 17%
Depression 17%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ketorolac tromethamine, per 15 mg J1885 Office 16 68 $38
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 29 283 $24
Injection, ceftriaxone sodium, per 250 mg J0696 Office 14 63 $23

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $98
$98 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $42
$42 34 —
VRAYLAR
  • AbbVie, Inc. $37
$37 12 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $19
$19 24 —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

51 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record